MISSION Leadership and Members Research Meetings Patient Resources News Contact
Partnerships


APS ACTION International Clinical Database and Repository:

2000 persistently aPL-positive patients whose natural course will be followed over a 10-year period. Information gathered through the Registry will facilitate a better assessment of aPL-related clinical problems and may help determine optimal management of aPL-positive patients. For more information about the APS ACTION registry, please click here.

Table 1: APS ACTION Centers Participating in the International Clinical Database and Repository


Center Name Investigator(s) (*) Contact Person
Hospital for Special Surgery
New York, NY, USA
Doruk Erkan
Jane Salmon
Michael Lockshin
JoAnn Vega*
vegaj@hss.edu
(1) 212-774-2795
University of Brescia
Brescia, Italy
Cecilia Nalli
Laura Andreoli
Angela Tincani*
tincani@med.unibs.it
reumatologia.immunologia@spedalicivili.brescia.it
(39) 030 3995488/7
University of Texas Medical Branch
Galveston, TX, USA
Silvia Pierangeli* sspieran@utmb.edu
University of Rio de Janeiro
Rio de Janeiro, Brazil
Guilherme de Jesus*
Roger Levy
guilhermedejesus@gmail.com
(55) 21 9959-4089
University of Athens
Athens, Greece
Maria Tektonidou* mtektonidou@gmail.com
(0030) 2132061786
University of Milan
Milan, Italy
Cecilia B. Chighizola*
Pierluigi Meroni

cecilia.chighizola@unimi.it
(39) 02 619112554

University Hospital
Padova, Italy
Alessandra Banzato
Vittorio Pengo*
vittorio.pengo@unipd.it
(39) 04 98215658
University of São Paulo
São Paulo, Brazil
Danieli Oliveira de Andrade* danieli.andrade@hc.fm.usp.br
(55) 11-30617176
University of Utah
Salt Lake City, UT, USA
Ware D. Branch* dwbranch@gmail.com
(1) 801-581-8425
Hospital Universitario Cruces
Bizkaia, Spain
Guillermo Ruiz-Irastorza* r.irastorza@euskaltel.net
(34) 946006348
Peking University First Hospital
Beijing, China
Zhuoli Zhang Ji Lanlan, MD*
thigh0829@163.com
(0086) 13810485376
Hospital Clinic
Barcelona, Catalonia, Spain
Guillermo Pons-Estel
Richard Cervera*
rcervera@clinic.ub.es
(34) 93 2275774
Hokkaido University Hospital
Sapporo, Japan
Tatsuya Atsumi* at3tat@med.hokudai.ac.jp
(81) 11-706-5913
Johns Hopkins University
Baltimore, MD, USA
Michelle Petri* mpetri@jhmi.edu
(1) 410-955-9114
Nancy University
Nancy, France
Denis Wahl* d.wahl@chu-nancy.fr
(33) 383153869
CHU de Québec, pavillon CHUL
Quebec, Canada
Paul R. Fortin Davy Eng*
Davy.Eng@crchuq.ulaval.ca
(1) 418-525-4444 ext. 48280

*Contact name/investigator

A Multicenter International Prospective, Randomized Controlled Trial of Hydroxychloroquine (HCQ) for the Primary Thrombosis Prevention in Persistently Antiphospholipid Antibody Positive but Thrombosis Free Patients Without Other Systemic Autoimmune Diseases


1000 patients will be randomized to standard of care versus standard of care plus HCQ. The purpose of this study is to determine whether HCQ is beneficial in reducing the blood clot formation in aPL-positive patients with no history of thrombosis.

Table 2: APS ACTION Centers Participating in the Hydroxychloroquine Trial:


Center Name Investigator(s) (*) Contact Person
Hospital for Special Surgery
New York, NY, USA
Doruk Erkan
Jane Salmon
Michael Lockshin
JoAnn Vega*
vegaj@hss.edu
(1) 212-774-2795
University of Texas Medical Branch
Galveston, TX, USA
Silvia Pierangeli* sspieran@utmb.edu
University of Athens
Athens, Greece
Maria Tektonidou* mtektonidou@gmail.com
(0030) 2132061786
University of Utah
Salt Lake City, UT, USA
Ware D. Branch* dwbranch@gmail.com
(1) 801-581-8425
Peking University First Hospital
Beijing, China
Zhuoli Zhang Ji Lanlan, MD*
thigh0829@163.com
(0086) 13810485376

*Contact name/investigator
**For general information about the above studies, please contact the APS ACTION Lead Coordinator, JoAnn Vega at vegaj@hss.edu.




2014

Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, Bertolaccini ML; on behalf of APS Action. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 2014 Jun 18. [Epub ahead of print]

2013

Andreoli L, Banzato A, Chighizola, CB, Pons-Estel GJ, Ramires de Jesus G, and Erkan D on Behalf of APS ACTION. The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infraction, and Deep Vein Thrombosis. Arthritis Care Res (Hoboken)2013;65(11):1869-1873.

Chighizola C, Andreoli L, Banzato A, de Jesus G, Pons-Estel G, Erkan D, and on Behalf of APS ACTION. The Association Between Antiphospolipid Antibodies and Related Clinical Outcomes: A Critical Review Of The Literature. Arthritis & Rheumatism 2013;65(10): S1129 (abstract).


2012

Andreoli L, Banzato A, Chighizola CB, Pons-Estel GJ, Ramires de Jesus G, Lockshin MD, and Erkan D on Behalf of APS ACTION. The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infarction, and Deep Vein Thrombosis. Arthritis & Rheumatism 2012;64(10): S1035 (abstract).

Chighizola CB, Ramires de Jesus G, Andreoli L, Banzato A, Pons-Estel GJ, Lockshin MD, and Erkan D on Behalf of APS ACTION. The Estimated Prevalence of Antiphospholipid Antibodies in the General Population with Pregnancy Morbidity. Arthritis & Rheumatism 2012;64(10): S744 (abstract).

Levy R, Jesus GR. “APS ACTION no Brasil”. Brazilian Journal of Rheumatology, 2012; 52 (5): 811-4.

Vega J, Greenberg A, and Erkan D. “Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)”. The Newsletter of the APS Foundation of America. Volume 24. Winter/Spring 2012. http://www.apsfa.org/docs/APSFAVol24WinSpr2012.pdf

Erkan D, Lockshin MD, on behalf of APS ACTION Members. APS ACTION - AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus 2012; 21:695-698

Erkan D, Pierangeli S, Locksin MD. “Task Force Report on Antiphospholipid Syndrome Clinical Research.” In: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies, 1st edition. Eds: Erkan, Pierangeli. Springer, 2012; 247-257


2011

Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin MD. Antiphospholipid Syndrome Clinical Research Task Force Report. Lupus 2011;20:219-224.



National or international APS clinical research studies that have been conducted based on the collaborative efforts of APS ACTION members:

Project Name Principal Investigator(s) APS ACTION Collaborators Start Date Current Status More Information
Euro-Phospholipid Project Ricard Cervera Ronald Derksen, Munther Khamashta, Pier Luigi Meroni, Phlipp De Groot, Angela Tincani 2001 Active Eurolupus

Catastrophic APS Registry

Ricard Cervera Doruk Erkan 1998 Active CAPS Registry
PROMISSE: Predictors of Pregnancy Outcomes in APS and SLE Jane Salmon Ware Branch,
Michael Lockshin,
Munther Khamashta
2003 Active Clinicaltrials.gov
RITAPS: A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of APS Doruk Erkan Michael Lockshin 2007 Closed Clinicaltrials.gov
Effects of Fluvastatin on Pro-inflammatory and Pro-thrombotic Markers in APS Patients

Doruk Erkan,
Silvia Pierangeli

Michael Lockshin 2008 Closed Clinicaltrials.gov
Stroke and aPL: Community-Based Clinicopathological Study Steven Levine

Jacob Rand

2009 Active Nih.gov
Effects of Hydroxychloroquine on the Annexin A5 Resistance Assay in aPL-Positive Patients with and without SLE Doruk Erkan

Michael Lockshin, Jacob Rand

2011 Closed Alana Levine,
MD at hcqstudy@hss.edu